Search This Blog

Saturday, March 28, 2026

Kymera Therapeutics Presents KT-621 BroADen Data at Dermatology Meet

 Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile

Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late-2027, respectively

https://www.globenewswire.com/news-release/2026/03/28/3264183/0/en/kymera-therapeutics-presents-kt-621-broaden-data-in-late-breaking-research-session-at-the-american-academy-of-dermatology-aad-annual-meeting.html

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)